Melanotan 2 Side Effects Beyond the Tan

The pitch arrives in a fifteen-second video that never mentions melanotan 2 side effects: a small vial or a nasal spray, a deep tan without the sun, and a nickname — "the Barbie drug" — that now has its own dermatology-journal literature (Orr 2025). The marketing got loud enough that TikTok removed promotional videos and banned hashtags including #melanotan2 and #nasaltanningspray, and sellers adapted by shipping the same sprays in plain packaging with "melanotan" left off the label (LegitScript, April 2024).

Set against that volume, the prospective human record remains small: it includes the 1996 three-man pilot and controlled studies published in 1998 and 2000 that each enrolled ten men, while broader safety information comes mainly from case reports and regulator records.

One tan, four receptors

Melanotan II is a lactam-bridged cyclic heptapeptide modeled on α-melanocyte-stimulating hormone (α-MSH), designed at the University of Arizona in the 1980s and described in its first human study as having "superpotent melanotropic activity in vitro" (Dorr 1996). It activates four of the five human melanocortin receptors — MC1R, MC3R, MC4R, and MC5R — and only one of them produces the tan.

That one is MC1R, on melanocytes: activation raises cAMP, which switches on protein kinase A, which upregulates tyrosinase — the rate-limiting enzyme of melanin synthesis — so the cell builds more eumelanin, the brown-black pigment, and passes it to surrounding skin cells. This runs without UV light — pigment appears with or without sun — and a 2025 review adds that the drug "exaggerates UV-mediated tanning" (Böhm 2025).

The other three come along for the ride: MC4R, in the hypothalamus and brainstem, governs appetite and sexual function — so a drug aimed at skin color also suppresses hunger and triggers erections through a central, nitric-oxide-dependent pathway independent of arousal — while MC3R sits in energy-balance circuits and MC5R in exocrine glands and muscle. Nearly every documented melanotan 2 side effect is an off-target receptor switched on alongside the intended one.

Melanotan 2 side effects: the documented record

The first prospective evidence was a pilot study: three healthy men received subcutaneous melanotan II over two weeks at doses between 0.01 and 0.03 mg per kilogram (Dorr 1996). The findings: mild nausea at most dose levels, Grade II somnolence and fatigue in one of the two men at the top dose, and spontaneous penile erections — intermittent, 1–5 hours after dosing, dose-dependent. Two of the three developed measurable pigmentation, still present a week after dosing ended.

The paper carries one detail no seller quotes: "a stretching and yawning complex appeared to correlate with the onset of spontaneous, penile erections." Three participants, n = 3 — too small to define the compound's safety profile.

Everything sharper-edged lives in the case-report literature and regulator files:

The confident incidence percentages that circulate on seller sites and forums trace to no published study — what the record supports is the list above: small trials, published case reports, and regulator harm listings (Gilhooley 2021 documents the forum culture filling the gap).

Moles, melanoma, and pigment that lingers

Melanotan II darkens existing moles and freckles faster than the surrounding skin and can enlarge them or bring out new ones; melanoma has now been reported in at least three published cases involving melanotan exposure, without establishing causation (Vadner & Smith 2026). Causation has not been established — but the pigment changes are well documented, and some outlast the drug by months.

Eruptive moles under melanocortin exposure carry their own review literature (Burian & Jemec 2019), and Australia's regulator lists increased moles and freckles among reported harms. Two of the melanoma reports: a 20-year-old woman with Fitzpatrick type II skin who injected melanotan II for three to four weeks alongside sunbeds and had a melanoma excised three months later — framed by her physicians as coinciding with use, not caused by it (Hjuler & Lorentzen 2014) — and a 22-year-old woman who developed oral mucosal melanoma after using melanotan II nasal spray, treated with resection and ongoing immunotherapy (Yassin Alsabbagh 2025) — a report whose own title ends in a question mark.

The balanced reading: selective MC1R activation by itself has not been associated with increased melanoma incidence; the concern attaches to melanotan II's non-selective pharmacology combined with the sun-seeking behavior of the people using it — and MC1R activation "importantly does not prevent melanoma" (Böhm 2025). A tan is not sunscreen.

Two more pigment facts. Response tracks MC1R genetics more than skin tone: people with loss-of-function MC1R variants — often fair-skinned and red-haired, the group most drawn to a tanning shortcut — mount a reduced pigment response to melanocortin agonists (Wolf Horrell 2016). And pigment can settle where nobody wants it: in a 2026 Life case report, a patient who self-injected melanotan II over 64 days developed near-symmetric brown pigmentation of the gums — mostly cleared from the cheeks a month after stopping, still visible on the gums at three months (Bonchev 2026).

What is inside the vials

When chemists measured melanotan II products bought from three online shops, no vial matched its label. Measured content ran 4.32–8.84 mg against a claimed 10 mg, and vials from two of the three shops carried unknown impurities at 4.1–5.9% (Breindahl 2015).

Read that as a dosing problem, not just a purity problem: a forum protocol has you dosing from a label that may overstate contents by half, from a vial that is several percent something no laboratory has identified. The market has since become harder to see into — sellers increasingly ship generically packaged nasal sprays with the drug's name removed, so the buyer cannot even name what they bought (LegitScript, April 2024). Australia's TGA warned in January 2025 that melanotan tanning products, nasal sprays included, were being illegally sold online; its harm listing for melanotan II includes reports of kidney dysfunction and swelling of the brain.

Where the law stands

In the United States, melanotan II is not FDA-approved for any medical use; selling it for human use violates the Food, Drug, and Cosmetic Act, and a product promising a tan without UV would need premarket approval it does not have. It is not a DEA-scheduled substance, so simple possession is not a federal crime — the law operates on sale and marketing.

The FDA has been on record since at least 2007, when it warned a company marketing injectable melanotan II as a tanning agent and making additional skin-cancer and rosacea claims, which made the product a drug rather than a cosmetic. The operative fact is newer: FDA now lists melanotan II among 503A bulk substances whose nominations were withdrawn (FDA safety-risk page). FDA plans to consult its Pharmacy Compounding Advisory Committee about melanotan II before the end of February 2027 (FDA meeting page); that review is advisory. Melanotan II is coming soon to Promise — add me to the list; it is prescription-only and will not be offered for cosmetic or appearance-related use. Regulatory status is one input into care, and a licensed provider may still prescribe a compounded formulation when appropriate; that decision belongs to the patient and prescriber.

Elsewhere the posture is similar or stricter. In the UK, no melanotan tanning product holds a marketing authorization; an afamelanotide (melanotan I) implant is licensed there only to prevent phototoxicity in adults with erythropoietic protoporphyria (NICE, 2023). The MHRA has warned about the tanning products and moved against sellers since 2008–2009 — suspending more than 100 websites illegally trading melanotan in a single 12-month period and closing 72 supplying UK customers inside three months, a posture reconfirmed by a 2022 freedom-of-information response. In Australia, supplying melanotan tanning products without a doctor's prescription is illegal whatever the form, and so is advertising melanotan to the public under the Therapeutic Goods Act, influencer posts included (TGA, January 2025); an afamelanotide implant has been registered there since 2020 for the same rare condition (TGA decision summary).

The family's two prescription drugs

Here is the part the tanning-video economy never mentions: two close relatives of melanotan II became real prescription drugs — each one tested in trials, approved for one narrow use, and kept under prescriber control.

The older one is afamelanotide, which is melanotan I: a linear α-MSH analog that acts mainly at MC1R, first described in 1980 (Sawyer 1980). Melanotan II came later from the same University of Arizona group — a shorter, cyclic analog whose design built on it (Al-Obeidi 1989) — so afamelanotide is melanotan II's predecessor, not its descendant. It was FDA-approved as SCENESSE (not the form Promise will offer) on October 8, 2019, for adults with erythropoietic protoporphyria, a rare disorder of painful light sensitivity — administered as an implant placed by a clinician every two months, not a self-injected vial.

The younger one is bremelanotide, better known as PT-141, developed from melanotan II itself (Hadley & Dorr 2006): the same ring with its C-terminal amide converted to a free acid, still active at several melanocortin receptors — its label names MC1R and MC4R as the most relevant at therapeutic doses (Vyleesi label) — and FDA-approved as Vyleesi (not the form offered through Promise) on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Promise's PT-141 is a compounded formulation — not FDA-approved — available only by prescription: a licensed provider reviews every request, not everyone qualifies, and the provider can decline on medical grounds.

Not everyone who finds melanotan II is chasing the tan; for many, the draw is the libido effect. If desire is the thread that led you here, the studied, provider-gated option is bremelanotide above; kisspeptin, coming soon to Promise, is a hypothalamic peptide upstream of the reproductive hormone axis with its own studied role in desire, distinct from the melanocortin arousal signal. Our explainer on what kisspeptin does covers that pathway in depth.

If you have already used melanotan 2

The useful answer is a list:

1. Stop, and keep the packaging. Whatever remains — vial, spray, box — helps a clinician identify what you were exposed to, given how often contents and labels disagree.
2. Tell your doctor and a dermatologist exactly what you used, by what route, and for how long. Clinicians handle this disclosure without drama, and it changes what they look for.
3. Get a full-body skin exam with photographic documentation of your moles — the surveillance the safety literature recommends for high-risk skin. New, changing, or darkening moles are a reason to be seen promptly. And an erection lasting more than four hours is an emergency-department visit: in one published case, the patient's erectile function had still not recovered four weeks after treatment (Dreyer 2019).

A safer conversation about tanning peptides

The melanotan II record reads the way it does because the drug skipped the process that catches problems: after a handful of small human trials, its development moved to internet storefronts, and its safety file has been written since by emergency departments and dermatology clinics. The molecules that stayed in the process came out narrower, studied, and prescribable — the difference between a compound and a medicine.

If what drew you to the videos still matters, bring a clinician into the loop: a dermatologist for the skin you have, and a prescriber for any goal a prescription product has been studied for. The conversation asks nothing but candor — and it is the one place in this story where you decide with full information.

This article is for education only and is not medical advice. Talk with a licensed healthcare provider about your own situation before starting or stopping any treatment.